Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) inspected the Unit I, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Koltur Village, Shameerpet, Medchal District, Telangana, from 17th July to 26thth July 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI).
The above information is a part of company’s filings submitted to BSE.
